$143.92
-0.43-0.30%
Pre-Market: 5:55 PM EDT
15 minutes delayed
TransMedics Gr
TMDXNASDAQ
want to know what
the Bulls & Bears Say?
TransMedics Gr (NASDAQ:TMDX) Stock, Analyst Ratings, Price Targets, Forecasts
TransMedics Group Inc has a consensus price target of $112.58 based on the ratings of 13 analysts. The high is $175 issued by TD Cowen on June 7, 2024. The low is $15 issued by Morgan Stanley on February 25, 2022. The 3 most-recent analyst ratings were released by Morgan Stanley, Piper Sandler, and Piper Sandler on July 15, 2024, July 15, 2024, and June 21, 2024, respectively. With an average price target of $145 between Morgan Stanley, Piper Sandler, and Piper Sandler, there's an implied 0.75% upside for TransMedics Group Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Piper Sandler
TD Cowen
Stephens & Co.
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for TransMedics Gr
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/15/2024 | Buy Now | 0.75% | Morgan Stanley | Patrick Wood | $104 → $145 | Maintains | Equal-Weight | Get Alert |
| 07/15/2024 | Buy Now | 18.12% | Piper Sandler | Matt O'Brien | $120 → $170 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | -16.62% | Piper Sandler | Matt O'Brien | $120 → $120 | Maintains | Overweight | Get Alert |
| 06/07/2024 | Buy Now | 21.6% | TD Cowen | Joshua Jennings | $130 → $175 | Maintains | Buy | Get Alert |
| 06/04/2024 | Buy Now | 4.92% | Stephens & Co. | George Sellers | → $151 | Initiates | → Overweight | Get Alert |
| 05/01/2024 | Buy Now | -18.7% | Canaccord Genuity | Jason Mills | $102 → $117 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | -9.67% | TD Cowen | Joshua Jennings | $100 → $130 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | -11.76% | JP Morgan | Allen Gong | $105 → $127 | Maintains | Overweight | Get Alert |
| 05/01/2024 | Buy Now | -16.62% | Piper Sandler | Matt O'Brien | $95 → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 05/01/2024 | Buy Now | -13.15% | Oppenheimer | Suraj Kalia | $105 → $125 | Maintains | Outperform | Get Alert |
| 03/28/2024 | Buy Now | -33.99% | Piper Sandler | Matt O'Brien | → $95 | Initiates | → Overweight | Get Alert |
| 02/28/2024 | Buy Now | -33.99% | Morgan Stanley | Cecilia Furlong | $75 → $95 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | -27.04% | JP Morgan | Allen Gong | $87 → $105 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | -27.04% | Oppenheimer | Suraj Kalia | $92 → $105 | Maintains | Outperform | Get Alert |
| 12/04/2023 | Buy Now | -47.89% | Morgan Stanley | Cecilia Furlong | $54 → $75 | Maintains | Equal-Weight | Get Alert |
| 11/07/2023 | Buy Now | -51.36% | JP Morgan | Thomas Allen | $67 → $70 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | -62.48% | Morgan Stanley | Cecilia Furlong | $50 → $54 | Maintains | Equal-Weight | Get Alert |
| 10/13/2023 | Buy Now | -65.26% | Morgan Stanley | Cecilia Furlong | $81 → $50 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | -23.57% | TD Cowen | Joshua Jennings | $95 → $110 | Maintains | Outperform | Get Alert |
| 07/19/2023 | Buy Now | — | William Blair | — | — | Initiates | → Outperform | Get Alert |
| 05/18/2023 | Buy Now | -40.24% | Canaccord Genuity | William Plovanic | $91 → $86 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | -43.72% | Morgan Stanley | Cecilia Furlong | $74 → $81 | Maintains | Equal-Weight | Get Alert |
| 05/02/2023 | Buy Now | -37.47% | Oppenheimer | Suraj Kalia | $85 → $90 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -47.89% | Cowen & Co. | Joshua Jennings | $70 → $75 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -45.8% | Canaccord Genuity | William Plovanic | $68 → $78 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | -43.72% | JP Morgan | Thomas Allen | $67 → $81 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -40.94% | Oppenheimer | Suraj Kalia | $55 → $85 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -48.58% | Morgan Stanley | Cecilia Furlong | $63 → $74 | Maintains | Equal-Weight | Get Alert |
| 01/06/2023 | Buy Now | -56.23% | Morgan Stanley | Cecilia Furlong | $54 → $63 | Maintains | Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | -62.48% | Morgan Stanley | Cecilia Furlong | $45 → $54 | Maintains | Equal-Weight | Get Alert |
| 10/11/2022 | Buy Now | -68.73% | Morgan Stanley | Cecilia Furlong | $37 → $45 | Maintains | Equal-Weight | Get Alert |
| 08/03/2022 | Buy Now | -74.29% | Morgan Stanley | Cecilia Furlong | $34 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/02/2022 | Buy Now | -68.73% | Oppenheimer | Suraj Kalia | $40 → $45 | Maintains | Outperform | Get Alert |
| 08/02/2022 | Buy Now | -66.65% | JP Morgan | Allen Gong | $26 → $48 | Upgrade | Neutral → Overweight | Get Alert |
| 07/26/2022 | Buy Now | -68.73% | Cowen & Co. | Joshua Jennings | $39 → $45 | Maintains | Outperform | Get Alert |
| 06/29/2022 | Buy Now | -76.38% | Morgan Stanley | Cecilia Furlong | $25 → $34 | Maintains | Equal-Weight | Get Alert |
| 06/28/2022 | Buy Now | -72.9% | Cowen & Co. | Joshua Jennings | $35 → $39 | Maintains | Outperform | Get Alert |
| 05/04/2022 | Buy Now | -82.63% | Morgan Stanley | Cecilia Furlong | $15 → $25 | Maintains | Equal-Weight | Get Alert |
| 03/17/2022 | Buy Now | -72.9% | Canaccord Genuity | William Plovanic | $38 → $39 | Maintains | Buy | Get Alert |
| 02/25/2022 | Buy Now | -89.58% | Morgan Stanley | David Lewis | $22 → $15 | Maintains | Equal-Weight | Get Alert |
| 01/07/2022 | Buy Now | -84.71% | Morgan Stanley | David Lewis | $33 → $22 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for TransMedics Gr (TMDX) stock?
The latest price target for TransMedics Gr (NASDAQ:TMDX) was reported by Morgan Stanley on July 15, 2024. The analyst firm set a price target for $145.00 expecting TMDX to rise to within 12 months (a possible 0.75% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TransMedics Gr (TMDX)?
The latest analyst rating for TransMedics Gr (NASDAQ:TMDX) was provided by Morgan Stanley, and TransMedics Gr maintained their equal-weight rating.
When was the last upgrade for TransMedics Gr (TMDX)?
The last upgrade for TransMedics Group Inc happened on August 2, 2022 when JP Morgan raised their price target to $48. JP Morgan previously had a neutral for TransMedics Group Inc.
When was the last downgrade for TransMedics Gr (TMDX)?
There is no last downgrade for TransMedics Gr.
When is the next analyst rating going to be posted or updated for TransMedics Gr (TMDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransMedics Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransMedics Gr was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.
Is the Analyst Rating TransMedics Gr (TMDX) correct?
While ratings are subjective and will change, the latest TransMedics Gr (TMDX) rating was a maintained with a price target of $104.00 to $145.00. The current price TransMedics Gr (TMDX) is trading at is $143.92, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.